[go: up one dir, main page]

AR117446A1 - ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF - Google Patents

ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF

Info

Publication number
AR117446A1
AR117446A1 ARP190103765A ARP190103765A AR117446A1 AR 117446 A1 AR117446 A1 AR 117446A1 AR P190103765 A ARP190103765 A AR P190103765A AR P190103765 A ARP190103765 A AR P190103765A AR 117446 A1 AR117446 A1 AR 117446A1
Authority
AR
Argentina
Prior art keywords
antibodies
antigen
binding fragments
conjugates
methods
Prior art date
Application number
ARP190103765A
Other languages
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR117446A1 publication Critical patent/AR117446A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente solicitud describe anticuerpos anti-PMEL17, fragmentos de unión a antígeno de los mismos, y conjugados de anticuerpo fármaco de dichos anticuerpos o fragmentos de unión a antígeno conjugados a un inhibidor de GNAQ / GNA11. La presente además se refiere a métodos para tratar o prevenir el cáncer usando los anticuerpos, fragmentos de unión a antígeno, y conjugados de anticuerpo fármaco. Además se describen métodos de preparación de anticuerpos, fragmentos de unión a antígeno, y conjugados de anticuerpo fármaco, y métodos de uso de los anticuerpos y fragmentos de unión a antígeno como reactivos de diagnóstico.The present application describes anti-PMEL17 antibodies, antigen-binding fragments thereof, and drug antibody conjugates of such antibodies or antigen-binding fragments conjugated to a GNAQ / GNA11 inhibitor. The present further relates to methods of treating or preventing cancer using the antibodies, antigen-binding fragments, and antibody-drug conjugates. In addition, methods of preparing antibodies, antigen-binding fragments, and antibody-drug conjugates, and methods of using the antibodies and antigen-binding fragments as diagnostic reagents are described.

ARP190103765A 2018-12-21 2019-12-19 ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF AR117446A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862783565P 2018-12-21 2018-12-21

Publications (1)

Publication Number Publication Date
AR117446A1 true AR117446A1 (en) 2021-08-04

Family

ID=77568195

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP190103765A AR117446A1 (en) 2018-12-21 2019-12-19 ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF
ARP210101664A AR122660A2 (en) 2018-12-21 2021-06-17 ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP210101664A AR122660A2 (en) 2018-12-21 2021-06-17 ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF

Country Status (1)

Country Link
AR (2) AR117446A1 (en)

Also Published As

Publication number Publication date
AR122660A2 (en) 2022-09-28

Similar Documents

Publication Publication Date Title
ECSP21044421A (en) ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF
AR102649A1 (en) ANTI-CADHERINA-P ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
MX2025000370A (en) Anti-ctla4 antibodies and methods of making and using the same
BR112021023229A2 (en) mcl-1 inhibitor antibody-drug conjugates and methods of use
MX2024001803A (en) ANTI-TREM2 ANTIBODIES AND METHODS OF USING THEM.
AR110920A1 (en) ANTI-CCR7 ANTIBODY DRUG CONJUGATES
MX2018007089A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof.
BR112016020752A2 (en) Isolated antibody or antigen-binding fragment thereof, pharmaceutical composition, and methods for treating a cancer or tumor expressing egfrviii and for treating a cancer, reducing tumor growth and / or causing tumor regression in a patient ?
BR112017025080A2 (en) anti-cd123 antibody drug conjugated compound, antibody drug conjugated composition, method of treating a patient having a cd123 expressing cancer, pharmaceutical composition, and intact antibody or antigen binding fragment
BR112016024363A2 (en) antibody-drug conjugate and its use for cancer treatment
BR112017003194B8 (en) ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF THE SAME THAT SPECIFICALLY BINDS TO HUMAN LAG3, COMPOSITION, AND, USE OF THE ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT OF THESE AND THE COMPOSITION
CL2025001913A1 (en) Anti-nectin-4 antibody; conjugate comprising it; pharmaceutical composition; and its use.
CO2022007924A2 (en) Anti-mesothelin eribulin antibody drug conjugates and methods of use
BR112015027309A2 (en) antibody, composition, method of treatment and use of an antibody
BR112019023909A8 (en) USE OF AN IMMUNOCONJUGATE THAT BINDS FOLR1, AND, USE OF AN IMMUNOCONJUGATE THAT BINDS FOLR1 AND PEMBROLIZUMAB
CO2023002375A2 (en) Antibodies against ilt2 and use thereof
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
BR112016024214B8 (en) Partially humanized monoclonal antibody, pharmaceutical composition and use of a monoclonal antibody
BR112021016596A2 (en) Anti-pd-l1 antibody and its use
MX2020010110A (en) DRUG CONJUGATES OF CMET MONOCLONAL BINDING AGENTS, AND USES THEREOF.
AR117446A1 (en) ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF
MX2022008745A (en) ANTI-NKP30 ANTIBODIES AND METHODS OF USE.
MX2025010218A (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
CO2025013101A2 (en) Multispecific anti-CD3 antibodies and methods of use
CL2025001474A1 (en) Anti-CD137 antibodies and methods of use